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Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) has been a common nosocomial pathogen since the 1960s, and has become a major
problem in hospitals worldwide. Patients and the public are increasingly seeing MRSA and rates of MRSA infections as indicators of the
quality of patient care. The control measures aimed at reducing the spread of MRSA among hospitals and communities include the fol-
lowing: education of healthcare workers, with implementation and adherence to hand-washing practices; restriction of antibiotic use;
active surveillance cultures (ASCs); contact isolation of MRSA-positive patients; and pre-emptive isolation of high-risk patients. However,
despite these interventions, MRSA is still endemic in many hospitals worldwide. In particular, the role of ASCs is still under debate.
International guidelines suggest that extensive ASCs should only be used in intensive-care units (ICUs), and routine screening of all hos-
pital admissions is not usually advocated. Local decisions can be made on the basis of types of risk factor of non-ICU patients. Before
starting ASCs, laboratories should be prepared for the workload, and the turn-around time for screening tests should be reduced and
arrangements made to monitor the effectiveness of this intervention. Most recently, rapid methods for molecular detection of MRSA
colonization have been developed. Published studies differ in their settings (ICU, medical wards, surgical wards), choice of patient popu-
lation, severity of illness, hospital infection control measures, and study design. The existing evidence does not support the wide applica-
tion of rapid molecular screening for MRSA.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is now
considered to be a community, state, national and interna-
tional problem. Patients and the public are increasingly seeing
MRSA and rates of MRSA infections as indicators of the qual-
ity of patient care. In 2005, the European Antimicrobial Sur-
veillance System, a free network that connects more than
600 laboratories in 28 European countries, observed per-
centages of methicillin resistance in blood isolates of S. aur-
eus ranging from 0% in Iceland to 60% in Romania [1]. In the
same year, data from The Surveillance Network-USA, an
electronic surveillance network that collects microbiology
data from 300 clinical microbiology laboratories across the
USA, reported that MRSA rates were 59%, 55% and 48% for
strains from non-intensive-care unit patients, intensive care
unit (ICU) patients, and outpatients, respectively [2].
In addition, there has been growing public concern over
reports of severe infections in the community caused by
MRSA [3,4]. In March 2008, guidelines from the British Soci-
ety for Antimicrobial Chemotherapy Working Party on
Community-onset MRSA Infections proposed that MRSA
should be suspected in patients with community onset of
infection associated with ‘spider bites’, recurrent skin
abscess, recent travel to an endemic area, and risk factors
such as previous antibiotic therapy or hospitalization [5]. In
the USA, a population-based surveillance report from the
CDC described the epidemiological characteristics of invasive
MRSA disease in nine US communities. The majority of cases
were healthcare-associated (HCA) infections in patients with
well-established risk factors for MRSA. However, 14% of
these infections were ‘true’ community-acquired (CA) infec-
tions. More interestingly, molecular testing identiﬁed strains
that were historically associated with CA-MRSA outbreaks
from cultures in both hospital-onset and HCA infections in
all surveillance areas [6]. Similarly, Maree et al. [7] found an
increase in the SCCmecIV phenotype, from 17% in 1999 to
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56% in 2003 among 352 patients with hospital-acquired
MRSA isolates.
The control measures used to reduce the spread of MRSA
among hospitals and communities include the following: educa-
tion of healthcare workers, with implementation and audit of
hand-washing practices; active surveillance cultures (ASCs);
contact isolation of MRSA-positive patients; pre-emptive isola-
tion of high-risk patients; and restriction of antibiotic use.
However, despite these interventions, MRSA is still endemic in
many hospitals worldwide. The available evidence suggests that
a multidisciplinary approach is needed to address this problem.
Four steps might be suggested to reduce the MRSA preva-
lence: (i) prevention of selection of methicillin resistance (anti-
biotic stewardship); (ii) reduction in the pool of colonized
patients; (iii) prevention of infections in colonized patients; and
(iv) prevention of patient-to-patient transmission.
Reduction in the Pool of Colonized
Patients
Screening patients for carriage of MRSA and isolation of
those positive seems to have a signiﬁcant role in the reduc-
tion of the pool of colonized patients and in the prevention
of cross-transmission.
MRSA colonization can be determined by nasal, rectal and
wound sampling. Nasal screening gives the highest yield for
the detection of MRSA carriage, but at least one other site,
such as a wound, the throat or the perineum, should be
screened for maximal sensitivity [8,9]. A systematic review
including ten studies and 1170 patients estimated the risk of
infection following MRSA colonization. The analysis showed a
four-fold increase in the risk of infection after MRSA coloni-
zation, as compared with methicillin-susceptible S. aureus col-
onization [10]. Colonization with CA-MRSA strains seems to
increase the risk of infection as well. In a prospective obser-
vational study of US army soldiers, Elliss et al. [11] showed
that colonization with Panton–Valentine leukocidin-positive
strains of CA-MRSA was correlated with a signiﬁcant risk of
developing pyogenic soft tissue infection.
Practice guidelines for preventing nosocomial transmission
of MRSA strongly support the use of ASCs linked to isola-
tion and cohorting facilities [12,13]. Cooper et al. [14] pre-
sented evidence that intensive concerted interventions that
include isolation can substantially reduce MRSA infections.
However, a recent systematic review of the literature per-
formed by McGinigle et al. [15] summarized the evidence of
the efﬁcacy of ASCs in the ICU setting, and revealed that,
although most observation-based studies reported a signiﬁ-
cant reduction in MRSA infection after the application of
ASCs, the evidence was of poor quality and did not allow
deﬁnitive recommendations.
How are healthcare professionals to decide what is the
best and most effective approach to preventing transmission
of MRSA within the hospital? Where is the evidence?
The Search and Destroy (S&D) Strategy
Some countries have maintained low endemic levels of MRSA
by implementing nationwide control measures targeting
MRSA, such as the search and destroy (S&D) strategy. S&D
measures include the following: contact isolation for MRSA-
positive patients; pre-emptive isolation and screening for
high-risk patients; screening of patients and personnel when
an unexpected MRSA-positive patient is found; screening of
all healthcare workers and keeping carriers away from work
until decontamination is achieved; and closing wards to new
admissions when there is more than one carrier among hos-
pitalized patients. Bootsma et al. [16] presented a stochastic
three-hospital model and an analytical one-hospital model to
quantify the effectiveness of this strategy. These authors sug-
gested that a combined approach of screening and isolation
is effective, and that MRSA prevalence might be reduced to
<1% in high-endemicity settings by an S&D strategy and step-
wise interventions.
Active Surveillance Culture: Advantages
The role of ASC might be different according to the baseline
MRSA prevalence and hospital setting. In three ICUs in
France, the acquisition incidence of MRSA was reduced from
7% to 3% through multiple interventions, including ASC, con-
tact precautions, and use of alcohol hand-rub solution. All
patients were nasally screened at hospital admission and
weekly thereafter, and positive cases were subjected to con-
tact precautions [17]. Similar results were obtained in an 18-
month study in Colorado, USA. When all patients admitted
to ICUs and medical wards were screened at admission and
weekly, and compared with historical controls, the overall
rate of nosocomial MRSA infections was found to have signif-
icantly decreased [18].
The costs of a hospital-wide selective screening pro-
gramme were analysed for a 19-month period in a 700-bed
hospital with 23 000 admissions/year in Germany. The
screening programme was able to prevent 48% of predicted
nosocomial MRSA infections, saving a predicted €200 782,
with a net saving of €110 000 annually. The screening pro-
gramme became cost-effective at a low MRSA incidence rate.
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The major limitation of the study was that the authors did
not use real cost calculations, but instead hospital reimburse-
ment as a surrogate parameter [19].
Active Surveillance Culture: Disadvantages
Although more than 100 studies have reported controlling
MRSA with screening linked to isolation and cohorting, two
studies suggested that reporting culture results and isolating
colonized patients had no impact on the prevalence of hospi-
tal-acquired MRSA [20,21]. The ﬁrst study assessed the
effect of daily microbiological surveillance alone (e.g. without
report of culture results or isolation of colonized patients)
on the spread of S. aureus. During a 10-week period, surveil-
lance cultures were performed in 158 patients. There was
no cross-transmission among patients in the medical ICU
(MICU), despite ongoing introduction of MRSA and methicil-
lin-susceptible S. aureus pathogens [20]. Cepeda et al. [21]
conducted a 1-year study in the ICUs of two teaching hospi-
tals where admission and weekly screens were used to
ascertain the incidence of MRSA colonization. In the middle
6 months, MRSA-positive patients were not moved to a sin-
gle room or cohorted. Standard precautions were practised,
and hand hygiene was encouraged. Using Cox proportional
hazard analysis, there was no change in transmission of
MRSA. However, the study has many limitations. First, the
time that elapsed from admission to the results of cultures
was up to 4 days, and patients with a length of hospitaliza-
tion <48 h were excluded. This time would be sufﬁcient,
especially in a high-endemicity situation, to allow the spread
of MRSA by cross-transmission. Second, the low numbers of
care givers and patients might have had an important effect
on the ﬁnal outcome.
ASCs should form part of a multifactorial bundle of infec-
tion control measures targeting the spread of nosocomial
MRSA. However, because of a lack of evidence of its clinical
effectiveness and cost-effectiveness, routine screening of all
admissions to hospital is not advocated. In 2006, legislative
measures that mandate the use of ASCs to screen hospital-
ized patients for colonization by MRSA and vancomycin-
resistant enterococci (VRE) were introduced in two US
states. In response to these legislations, the Society for
Healthcare Epidemiology of America and the Association for
Professionals in Infection Control and Epidemiology Inc.
developed a position statement asserting that, although there
is good evidence to support the use of active surveillance for
high-risk patients and during outbreaks, there is not sufﬁcient
evidence to justify the mandatory use of this control
measure [22]. The reasons for the lack of support for this
legislation include the following: exclusion of local infection
control professionals from their role of leading risk assess-
ment and resource allocation; the unresolved controversies
regarding the epidemiological, biological and clinical implica-
tions of active surveillance; and the potentially negative
effects on patients of contact isolation [22].
Targeted Screening
Targeted surveillance of medical or surgical patients based
on risk factors might provide the most effective use of
resources. Many studies have analysed the epidemiological
characteristics of patients with MRSA colonization or infec-
tion at hospital admission [23–26], and Table 1 summarizes
the results. Risk factors for HCA-MRSA infections at hospital
admissions were analysed in 127 patients with septicaemia in
an endemic setting in Boston, USA. Two logistic regression
models were generated. In the ﬁrst model, previous MRSA
infection or colonization, cellulitis, presence of a central
venous catheter, and skin ulcers were independently associ-
ated with MRSA bacteraemia. Because prior MRSA coloniza-
tion or infection status may not be known at the time of
hospitalization, a second model was generated that excluded
prior history of MRSA colonization or infection. This model
identiﬁed the presence of a central venous catheter, hospital-
ization(s) within the previous 6 months, use of quinolones
within the previous 30 days, and diabetes mellitus as inde-
pendent risk factors for MRSA bacteraemia. Both models
had high sensitivity and speciﬁcity [23]. Harbarth et al. [24]
deﬁned risk factors for unknown carriage of MRSA at hospi-
tal admission in a university hospital in Geneva. Male sex, age
>75 years, previous exposure to quinolones, cephalosporins
and carbapenems, previous hospitalization, intra-hospital
transfer, and urinary catheterization were associated with
MRSA colonization at hospital admission. In a 1-year pro-
spective study including 700 adult patients admitted to medi-
cal and surgical wards of a tertiary-care facility, previous
hospital admission had the highest sensitivity in predicting
both MRSA and VRE colonization. In this study, 11% of the
patients were co-colonized with VRE and MRSA [25]. In a
surveillance study, independent risk measures for MRSA car-
riage at admission were a nursing home stay, prior MRSA
infection, and a third variable representing the combined
effects of homelessness, prison stay, promiscuity, intravenous
drug use, and other drug use. Multivariable models had
greater sensitivity at detecting MRSA at admission than any
single risk measure, and allowed detection of 78–90% of
MRSA-positive admission surveillance cultures in 46–58% of
admissions [26]. If conﬁrmed in other studies, multivariable
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questionnaire screening at admission might be the easiest
and least expensive way of identifying a subset of patients for
targeted screening.
Furuno et al. [25] compared estimated surveillance costs
associated with a prediction rule for targeted active surveil-
lance with hospital-wide, non-directed surveillance for MRSA
and VRE during an 8-month study period. Targeted screen-
ings showed signiﬁcant cost savings.
Personnel Screenings
The screening of healthcare workers remains controversial, as
the role of such detection in the colonization and infection of
patients is still under debate. There is little evidence to suggest
that exclusion of MRSA-positive personnel would lead to a
reduction in prevalence on the ward. Screening of staff is time-
consuming and costly, and has emotional, professional and
conﬁdentiality implications for those who test positive. How-
ever, screening of staff might have a role during outbreaks.
Rapid molecular Diagnosis
For several years, conventional culture methods, which can
take at least 48–72 h to give a result, have been considered
to be the reference standard for detection of MRSA coloni-
zation. However, in recent years, a number of different
molecular methods for the rapid detection of MRSA have
been described [27,28]. In the most common commercial
method, PCR primers amplify the right-hand extremity of
the SCCmec genetic element, which contains mecA, and orfX,
an open reading frame that is speciﬁc for S. aureus. High sen-
sitivity and speciﬁcity have been reported in several studies,
with results being available in 2 h [27,28]. The main obstacles
to the wide application of molecular screening for MRSA are
related to the high costs and varying beneﬁts in different
studies. Eleven studies analysed the impact of rapid molecular
tests on the incidence of MRSA nosocomial transmission and
infection [29–39] (Table 2). Eight studies were performed in
Europe in different settings: ICUs (three studies), medical
and/or surgery wards (six), and hospital-wide (two). Five
papers reported signiﬁcant decreases in the rates of nosoco-
mial MRSA colonization and/or infection [30,33–35,37].
The ﬁrst study to assess whether a molecular MRSA
screening test would decrease the time between ICU admis-
sion and identiﬁcation of MRSA carriers was performed by
Harbarth et al. in a surgical (SICU) and a MICU of a Swiss
hospital. All patients admitted for more than 24 h were
screened by PCR. The results were compared with a histori-
cal control period, when only patients at high risk for MRSA
colonization were screened, using conventional culture. Pre-
emptive isolation was applied to all patients in the last part
of the study in both ICUs. The authors observed a reduction
of time to notiﬁcation of up to 1 day and a reduction of
MRSA cross-infection in the MICU but not in the SICU.
These results might be explained as follows. First, the sensi-
tivity of the test was 84%, and the screening was performed
only at admission, and not at discharge. Second, the SICU
had already been presumptively isolating admitted patients at
high risk. Third, the topical decolonization agent chosen may
have been more effective for medical than for surgical
patients. Other possible confounders might have been differ-
ences between ICUs in terms of infection policies, antibiotic
use, compliance with hand hygiene, and case mix or stafﬁng
levels [29]. Cunningham et al. performed an interventional
cohort study in a mixed medical–surgical adult ICU. The
impact of rapid PCR screening on MRSA transmission was
TABLE 1. Risk factors for being colonized or infected with methicillin-resistant Staphylococcus aureus (MRSA) at hospital
admission
MRSA colonization HCA- MRSA infection CA- MRSA infection
Previous therapy with quinolones,
cephalosporins, or carbapenems
Previous hospitalization or surgery
Advanced age
Dialysis
Residency in LTCFs or NHs
Underlying chronic illness
Eczema, psoriasis, or dermatitis
History of homeless, promiscuity,
or prison
Pressure sores
Intravenous drug abuse
Previous therapy with quinolones,
cephalosporins, or carbapenems
Previous hospitalization, surgery,
or healthcare contacts
Previous MRSA colonization or infection
Dialysis
Indwelling bladder or vascular device
at home
Underlying chronic illness
Intravenous drug abuse
Residency in LTCFs or NHs,
intravenous therapy, or
specialized nursing at home
Pressure sores
Previous antibiotic therapy, in particular
quinolones and macrolides
Underlying chronic illness
Without risk factors
Groups with a higher incidence:
Athletes
Military personnel
Males having sex with males
Prison inmates
IV drug users
Homeless persons
Native Americans
Paciﬁc Islanders
Children in day-care programmes
Recent travel to an endemic area such
as North America
CA, community-acquired; HCA, healthcare-associated; IV, intravenous; LTCF, long-term-care facily; NH, nursing home.
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compared with that of a conventional culture method. Stan-
dard infection control precautions, including decolonization
treatment, were instituted for MRSA-positive patients. The
mean incidence of MRSA transmission (expressed as the
number of acquired cases per 1000 patient-days) decreased
from 13.9 during the culture phase to 4.9 during the PCR
phase [30].
A comparison between rapid molecular diagnosis in high-
risk patients (deﬁned as patients transferred from another
healthcare facility, hospitalized in the previous 6 months, and
with a history of MRSA colonization or infection) and con-
ventional cultures was performed in Canada. A time-series
analysis indicated an insigniﬁcant decrease of 0.14 cases per
1000 patient-days per month after the introduction of PCR.
Costs were higher for patients screened by PCR, owing to
the low positive predictive value of the test, which led to
the unnecessary use of contact precautions [31].
A cluster randomized cross-over trial was performed at a
UK teaching hospital where MRSA was endemic, involving
six surgical, two oncology and two elderly wards. All patients
admitted to the wards over a 14-month period were ran-
domized to receive either rapid screening for MRSA or con-
ventional culture screening. Rates of MRSA transmission and
infection were not statistically different between the two
arms. The rapid test led to reductions in median reporting
time from admission and the number of inappropriate pre-
emptive isolation days [32].
A 2-year interventional study was conducted in a cardiac
surgery unit of a large UK teaching hospital, to determine
the impact of rapid preoperative detection of MRSA on the
development of surgical site infections (SSIs) in patients
undergoing cardiac surgery, as compared with the preceding
control period, when patients were not screened. Topical
MRSA decolonization therapy was immediately commenced
according to the PCR results. The rate of SSI signiﬁcantly
decreased from 3.3% to 2.2% [33].
An interventional study performed in a three-hospital
organization examined the effect of two expanded surveil-
lance interventions on MRSA infections. The authors mea-
sured the utility of expanded surveillance for MRSA by using
a three-period before-and-after design: the ﬁrst 12-month
period was without active surveillance; during the second
12-month period MRSA surveillance was applied to all admis-
sions to the ICU; and in the third 21-month period MRSA
surveillance was universally applied to all hospital admissions.
Real-time PCR nasal surveillance for MRSA, followed by topi-
cal decolonization therapy and contact isolation were applied
during intervention periods 2 and 3. During universal surveil-
lance, the prevalence density of MRSA infections showed a
statistically signiﬁcant decrease [34].
An interventional study in a surgical population aimed to
establish the efﬁcacy of rapid molecular screening for MRSA
and topical suppression therapy on the rates of nosocomial
MRSA wound infection and bacteraemia. MRSA-positive
patients were decolonized with a standard protocol. The
overall rate of MRSA bacteraemia per 1000 patient-days
decreased signiﬁcantly (by 38.6%) as compared with historical
controls. In comparison to the annual mean for the preced-
ing 6 years, MRSA bacteraemias fell by 38.5% and MRSA
wound infections by 12.7% [35].
A prospective interventional cross-over cohort study con-
ducted among 21 754 surgical patients at a Swiss teaching
hospital was performed to determine the effect of early
MRSA detection on nosocomial MRSA infection rates as
compared with standard infection control without screening.
The study involved 12 surgical wards of different specialties,
assigned to either the control or intervention group for a
9-month period, and then switched over to the other group
for another 9 months. The rate of MRSA nosocomial infec-
tion did not change signiﬁcantly [36].
Aldeyab et al. [37] performed a prospective interventional
cohort study with a cross-over design in medical–cardiology
and surgical wards. Wards were assigned to receive either
rapid screening or culture screening. The MRSA acquisition
rate was not signiﬁcantly reduced.
A retrospective interventional cohort study included all
patients admitted to otorhinolaryngology, head and neck
oncology. Data were collected before and after a rapid
screening test was introduced. The use of rapid screening
did not reduce MRSA SSIs [38].
A recent systematic review and meta-analysis included all
of the above-mentioned ten studies [39]. Primary outcomes
were MRSA acquisition rate and incidence of MRSA bactera-
emia and SSI. As compared with conventional cultures, the
use of a rapid test for MRSA was not associated with a
decrease in the acquisition rate of MRSA. As compared with
standard infection control measures not including screening,
the use of a rapid test was associated with a decrease in bac-
teraemia but not in SSI [39]. These data seem to suggest that
in wards in which culture screening is applied, there is no
evidence to support the introduction of molecular tests to
signiﬁcantly reduce the rates of MRSA acquisition and SSI.
After the study period reviewed in the meta-analysis (July
1965 to February 2009), a prospective, cluster, two-period
cross-over design study including 12 682 patients in seven
surgical wards was published. Control wards performed con-
ventional cultures. Screening methods were switched after
8 months. Rapid screening was shown to reduce MRSA
acquisition to a statistically signiﬁcant extent. No data were
provided on the incidence of MRSA SSI [40].
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On the basis on these studies, deﬁnitive recommendations
cannot be made. The studies showed signiﬁcant heterogene-
ity, mainly related to different study designs, study popula-
tions, and hospital settings. The variability in the efﬁcacy of
PCR might be partially explained by the different compari-
sons used, which included comparison with no screening or
comparison with screening by conventional culture methods.
The other limitations include systematic screenings not being
performed at discharge or at follow-up, PCR results not
being conﬁrmed by conventional cultures, lack of analysis of
possible variation in MRSA epidemiology during the study
period, and failure to monitor adherence to decolonization
treatment or isolation contact precautions.
Conclusions
The measures required to control MRSA in hospitals where
the infection is highly endemic may be different from those
required in other institutions. On the basis of existing evi-
dence, only ICUs should apply extensive screening. Routine
screening of all admissions is not advocated. Local decisions
can be made on the basis of risk. Before starting ASCs, labo-
ratories should be prepared for the workload, the turn-
around time for screening tests should be reduced, and sys-
tems should be in place to monitor the effectiveness of the
intervention. Surveillance data should be collected and fed
back to all stakeholders.
Data on the impact of the rapid molecular diagnosis of MRSA
colonization are extremely heterogeneous. Published studies
differ in their settings (ICU, medical wards, surgery wards),
patient population, severity of illness, hospital infection control
measures (i.e. association with pre-emptive isolation and/or
decolonization protocol), and, most importantly, study design
and baseline prevalence of MRSA. At present, there is no evi-
dence available to support the wide application of these new
tests for the identiﬁcation of MRSA carriers.
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